GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GL...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/2/1703 |
| _version_ | 1797441095161872384 |
|---|---|
| author | Riccardo Nevola Raffaella Epifani Simona Imbriani Giovanni Tortorella Concetta Aprea Raffaele Galiero Luca Rinaldi Raffaele Marfella Ferdinando Carlo Sasso |
| author_facet | Riccardo Nevola Raffaella Epifani Simona Imbriani Giovanni Tortorella Concetta Aprea Raffaele Galiero Luca Rinaldi Raffaele Marfella Ferdinando Carlo Sasso |
| author_sort | Riccardo Nevola |
| collection | DOAJ |
| description | To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios. |
| first_indexed | 2024-03-09T12:18:05Z |
| format | Article |
| id | doaj.art-94edf73e442b4487939cccd0a37f2269 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T12:18:05Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-94edf73e442b4487939cccd0a37f22692023-11-30T22:44:23ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-01-01242170310.3390/ijms24021703GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future PerspectivesRiccardo Nevola0Raffaella Epifani1Simona Imbriani2Giovanni Tortorella3Concetta Aprea4Raffaele Galiero5Luca Rinaldi6Raffaele Marfella7Ferdinando Carlo Sasso8Department of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, Università Della Campania “Luigi Vanvitelli”, I-80131 Naples, ItalyTo date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.https://www.mdpi.com/1422-0067/24/2/1703NAFLDGLP-1 receptor agonisttype 2 diabetessteatosis |
| spellingShingle | Riccardo Nevola Raffaella Epifani Simona Imbriani Giovanni Tortorella Concetta Aprea Raffaele Galiero Luca Rinaldi Raffaele Marfella Ferdinando Carlo Sasso GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives International Journal of Molecular Sciences NAFLD GLP-1 receptor agonist type 2 diabetes steatosis |
| title | GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives |
| title_full | GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives |
| title_fullStr | GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives |
| title_full_unstemmed | GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives |
| title_short | GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives |
| title_sort | glp 1 receptor agonists in non alcoholic fatty liver disease current evidence and future perspectives |
| topic | NAFLD GLP-1 receptor agonist type 2 diabetes steatosis |
| url | https://www.mdpi.com/1422-0067/24/2/1703 |
| work_keys_str_mv | AT riccardonevola glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives AT raffaellaepifani glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives AT simonaimbriani glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives AT giovannitortorella glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives AT concettaaprea glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives AT raffaelegaliero glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives AT lucarinaldi glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives AT raffaelemarfella glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives AT ferdinandocarlosasso glp1receptoragonistsinnonalcoholicfattyliverdiseasecurrentevidenceandfutureperspectives |